AgomAb Therapeutics NV (AGMB) – What Are Brokerages Thinking About This Stock?

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $37.50.

AGMB has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. B. Riley Financial assumed coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating for the company. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Finally, Piper Sandler initiated coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective on the stock.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ AGMB opened at $7.49 on Friday. The company has a 50 day simple moving average of $10.92 and a two-hundred day simple moving average of $12.00. AgomAb Therapeutics has a 12 month low of $6.61 and a 12 month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Equities research analysts forecast that AgomAb Therapeutics will post -1.77 earnings per share for the current year.

Insider Activity at AgomAb Therapeutics

In other news, CEO Tim Jasper Knotnerus purchased 6,000 shares of the stock in a transaction dated Monday, October 5th. The shares were purchased at an average cost of $8.48 per share, with a total value of $50,880.00. Following the completion of the purchase, the chief executive officer directly owned 16,823 shares of the company’s stock, valued at approximately $142,659.04. The trade was a 55.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Pierre Kemula bought 10,000 shares of AgomAb Therapeutics stock in a transaction dated Tuesday, October 6th. The stock was acquired at an average price of $8.59 per share, with a total value of $85,900.00. Following the completion of the transaction, the chief financial officer directly owned 10,000 shares of the company’s stock, valued at approximately $85,900. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 41,000 shares of company stock valued at $357,080.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.